Snap Diagnostics competitors

Kevin S. Wilson has been Heska's Chief Executive Officer and President since March 31, 2014. He previously served as the President and Chief Operating Officer since February 2013. Mr. Wilson is a founder, member and officer of Cuattro, LLC. Since 2008, he has been involved in developing technologies for radiographic imaging with Cuattro, LLC and including as a founder of Cuattro Software, LLC, Cuattro Medical, LLC and Cuattro Veterinary, LLC. Mr. Wilson served on the board of various private, non-profit, and educational organizations from 2005 to 2011. He was a founder of Sound Technologies, Inc., a diagnostic imaging company, in 1996. After Sound Technologies, Inc. was sold to VCA Antech, Inc. in 2004, Mr. Wilson served as Chief Strategy Officer for VCA Antech, Inc. until 2006. Mr. Wilson attended Saddleback College.

Michael Els is a Chief Executive Officer at Orthofix and is based in Johannesburg, Gauteng, South Africa.

Kook Books is a Chief Executive Officer at I-Flow and is based in Haven, Kansas.

Jay Kranzler has been a Founder, CEO, Board Member, and Advisor to leading life science companies for over 30 years. He is currently acting as Founder and Chief Executive Officer of Perception Neuroscience, Acting Chief Medical Officer of Pastorus, Board Member of Pastorus, Avenue Pharmaceuticals, and ImmunoBrain Checkpoint, and Advisor to small and large companies in the pharma/ biotech space. After graduating from Yale University School of Medicine with MD and PhD degrees with a focus in psychopharmacology, Dr. Kranzler joined McKinsey & Company where he contributed toward founding the Firm’s pharmaceutical practice. In 1989, he became the Chief Executive Officer of Cytel Corporation, a company focused on the development of immunomodulatory drugs. He took Cytel public, and negotiated partnerships with both global and Japanese pharmaceutical companies that set new standards for deal size and structure. After Cytel, Dr. Kranzler became Chief Executive Officer of Cypress Bioscience (formerly IMRE Corporation) where he was credited for the development of Savella™ (milnacipran) for the treatment of fibromyalgia, and Karuna Pharmaceuticals, focusing on the treatment of Schizophrenia.

Accomplished Senior Executive with 20+ years of diverse healthcare market experience across the continuum of care: physician office, hospital, outpatient, integrated delivery networks (IDN), group purchasing (GPO), payer organizations, medical banking, retail and consumer directed healthcare. Demonstrated success in shaping corporate direction, designing and executing business strategies, building and leading sales and cross functional teams to deliver profitable results in a variety of corporate environments including: startup, rapid growth, turn-around, strategic repositioning and Fortune 100. Revenue responsibility for $1 million to $230 million enterprises. Extensive Board level interaction. Accomplishments include pioneering a first to market non-invasive medical technology, and a key role in a startup company's growth to $1 billion+ market valuation in six years (recognized by INC. Magazine as #1 Fastest Growing Company). Passion of a successful entrepreneur and the discipline of a seasoned executive. Specialties: B2B, B2C, B2B2C Start-up and early stage environment Commercialization strategies Implementation of complex healthcare technologies & services Forming & leading cross-functional field teams (sales, clinical, technical) Distribution channel & customer relationship management Domestic and international sales Strategic alliances GPO, and national accounts management Multiple therapeutic expertise Consumer directed health care (CDHC) Interim executive management Consulting Services

Larry Miller is an Instructor:Medicine at Harvard Medical School, Venture Partner at Sanderling Ventures, and Founding Partner at Mediphase Venture Partners and is based in Boston, Massachusetts. He has worked as Vice President at Hawaii Public Radio; Board Member at TETRAPHASE PHARMACEUTICALS INC; and Founder, General Partner at Mediphase. Lawrence studied at Harvard University until 1973, Harvard Medical School until 1978, and Massachusetts General Hospital and Harvard Medical School between 1978 and 1982.